Case Reports in Infectious Diseases

Case Reports in Infectious Diseases / 2019 / Article

Case Report | Open Access

Volume 2019 |Article ID 9315756 | 5 pages |

Fatal Balamuthia mandrillaris Encephalitis

Academic Editor: Larry M. Bush
Received26 Sep 2018
Revised01 Jan 2019
Accepted17 Jan 2019
Published31 Jan 2019


Balamuthia mandrillaris is a rare cause of granulomatous meningoencephalitis associated with high mortality. We report a 69-year-old Caucasian female who presented with a 3-day history of worsening confusion and difficulty with speech. On admission, she was disoriented and had expressive dysphasia. Motor examination revealed a right arm pronator drift. Cerebellar examination showed slowing of finger-nose testing on the left. She was HIV-negative, but the absolute CD4 count was low. Neuroimaging showed three cavitary, peripherally enhancing brain lesions, involving the right frontal lobe, the left basal ganglia, and the left cerebellar hemisphere. She underwent right frontal craniotomy with removal of tan, creamy, partially liquefied necrotic material from the brain, consistent with granulomatous amoebic encephalitis on tissue staining. Immunohistochemical studies and PCR tests confirmed infection with Balamuthia mandrillaris. She was started on pentamidine, sulfadiazine, azithromycin, fluconazole, flucytosine, and miltefosine. The postoperative course was complicated by an ischemic stroke, and she died a few weeks later.

1. Introduction

Balamuthia mandrillaris is a free-living heterotrophic amoeba found in soil. This organism can cause a rare and usually fatal granulomatous amebic encephalitis (GAE) in both immunocompetent and immunocompromised patients. Since the time that Balamuthia mandrillaris was first isolated, approximately 200 cases had been reported worldwide [1], and in the United States, there have been 94 cases reported to the CDC from 1976 to 2014 ( We report a case of Balamuthia encephalitis in an elderly woman who presented with altered mental status.

2. Case Presentation

A 69-year-old Caucasian female was brought to the emergency room by her family for worsening confusion that began 3 days prior to admission. Her son reported that she had not been acting like herself, had been confused, and had been sending him some gibberish text messages. They also noticed that the patient was very quiet, which was unusual for her. She had trouble finding words and her speech did not make sense. She seemed to be indifferent and inattentive at times and had urinary incontinence. There was no history of fever, chills, headache, nausea, vomiting, photophobia, diplopia, or seizure activity. She denied any skin rash or ulcers. She liked to garden in her free time.

Her general physical examination was unremarkable, and she was well-nourished. Vital signs were within normal limits. Ophthalmological examination revealed bilateral 3 mm reactive pupils with full conjugate extraocular movements and no nystagmus or ptosis. Visual acuity was 20/50 in the right eye and 20/100 in the left eye. Funduscopic examination revealed slightly blurred disk margins on the left, with sharp disk margins on the right; the retinal vascularity was normal. She was alert and cooperative and was oriented to self and time but not to place. She could add simple numbers but had difficulty with serial seven subtractions. She was slow to spell “world” backward. She spoke in short phrases and occasionally sentences. Her speech was fluent, but there was intermittent misuse of words and expressive dysphasia. Cranial nerves 2 through 12 were intact, except for a right eyelid droop. Motor examination revealed a slight pronator drift of the right arm. She had 5/5 muscle power in the upper and lower extremities, and her deep tendon reflexes were symmetric. Cerebellar examination showed slowing of the finger-nose testing and rapid alternating movements on the left but without tremor or dysmetria.

The complete blood count, metabolic panel, and inflammatory markers (ESR and CRP) were normal. She was HIV-negative, but the absolute CD4 count was 250/mm3 (reference range 500–1500/mm3). Neuroimaging showed centrally cavitary, peripherally enhancing intra-axial brain lesions, involving the right frontal lobe, the left basal ganglia, and the lateral aspect of the left cerebellar hemisphere (Figure 1). She was started on IV dexamethasone (10 mg bolus) followed by 4 mg every 6 hours for cerebral edema. She underwent right frontal craniotomy the next day with removal of tan, creamy, partially liquefied necrotic material, which was sent for histopathology and cultures. The final histopathology was consistent with granulomatous amebic encephalitis (Figure 2). Bacterial cultures were negative. Immunohistochemical and real-time PCR tests performed at the Centers for Disease Control and Prevention, Atlanta, GA, documented positive results for Balamuthia mandrillaris amoeba and negative immunohistochemical and real-time PCR results for Naegleria fowleri amoeba and Acanthamoeba species amoeba. DNA sequencing data were unavailable. As per the CDC recommendations, she was started empirically on a six-drug regimen of pentamidine (which has amoebastatic activity in vitro), sulfadiazine, azithromycin, fluconazole, flucytosine, and miltefosine (which has amebicidal activity in vitro). These treatment recommendations were mostly based on a few Balamuthia survivor case reports in the literature. Her hospital course was complicated by an ischemic stroke on postoperative day 3, and she clinically deteriorated with worsening mental status. Given the poor prognosis, her family decided to pursue hospice care, and she died a few weeks later.

3. Discussion

Balamuthia mandrillaris is a rare cause of granulomatous amebic encephalitis (GAE). This free-living amoeba was first isolated from the brain of a mandrill baboon that died at San Diego Zoo from a mysterious neurological illness [2]. B. mandrillaris is considered a close relative of Acanthamoeba and is placed in the family Acanthamoebidae [3]. Balamuthia mandrillaris may also harbor pathogenic bacteria in the natural environment such as Listeria monocytogenes, Vibrio cholerae, E. coli O157 : H7, Mycobacterium avium complex, Burkholderia pseudomallei, and Legionella pneumophila, thus potentiating their virulence and environmental survival [4]. The worrisome feature about Balamuthia mandrillaris is that it can cause GAE irrespective of the status of the host immune system, and this is a matter of grave concern as there are no definitive treatments available [5, 6]. Males are affected 2.5 times more frequently than females, perhaps because they are more exposed to soil through outdoor activities [5].

Those at high risk for this infection include people with HIV/AIDS, cancer, liver disease, or diabetes mellitus, people receiving immunosuppressive drugs, and alcoholics [1, 6]. This patient had idiopathic CD4 lymphopenia, which could have predisposed her to this rare infection. Patients at the extremes of age (under 15 years and over 60 years) appear to be more susceptible, which may be attributed to their weaker immune systems [7]. Most cases of BAE have been reported from the warmer regions, with South America and the southwestern United States (California, Texas, and Arizona) having the highest incidence [5, 8].

Balamuthia mandrillaris can be isolated from soil, and contact with contaminated soil is considered a major risk factor for contracting Balamuthia mandrillaris amebic encephalitis (BAE) [9, 10]. Our patient was a gardener; hence, the likely port of entry could have been through the skin. The life cycle of B. mandrillaris has two stages, the vegetative trophozoites and the dormant cyst. The trophozoites are the infective form, and they enter the human body either through inhalation or through a break in the skin. In most cases, a primary site of infection is not identified, but almost half of the survivors of B. mandrillaris GAE reported having an antecedent cutaneous lesion. Hence, it can be postulated that detection of skin lesions can lead to earlier diagnosis and more prompt antimicrobial drug treatment, which potentially could increase the patient’s chances of survival [11]. The incubation period varies from 1 to 30 days (with an average of 8.5 days), and the amoeba can invade the central nervous system by hematogenous dissemination causing GAE [5]. Circulating amoebae most likely gain access to the CNS through the blood-brain barrier (BBB). However, if B. mandrillaris is isolated from the CSF, a port of entry could be through the highly vascular choroid plexus [12]. The BBB is highly selective, restricting the entry of pathogens, although recent studies have shown that the human brain microvascular endothelial cells produce interleukin-6 (IL-6) in response to B. mandrillaris infection, and this may play a role in the traversal of the BBB [13]. Human-to-human disease transmission of the pathogen can occur through organ transplantation, and thus, brain-dead victims of Balamuthia encephalitis are not suitable organ donors [14, 15].

Unlike in the patient reported here, BAE often has a slow, insidious onset, which then develops into a subacute or chronic disease over several months to years. However, infections associated with organ transplantation have a rapid clinical course likely related to severe immunosuppression [14, 15]. Patients often present with behavioral and personality changes, confusion, seizures, and cranial nerve dysfunction. As the disease progresses, patients can have symptoms of increased intracranial pressure. Neuroimaging of GAE typically shows multiple, well-defined, focal, ring-enhancing, space-occupying lesions, with perilesional edema; ventriculomegaly and hydrocephalus have also been reported. Another hallmark is hemorrhage into the mass lesion [16, 17]. In patients with GAE due to B. mandrillaris, any cortical lobe can be involved: temporal (51%), frontal (41%), occipital (31%), and parietal (21%). Among extracortical sites, the cerebellum, thalamus, basal ganglia including the caudate nucleus, and the brainstem are the most favored sites [18]. As in our patient, angiitis secondary to amebic invasion can cause small vessel occlusions, resulting in cerebral infarction.

Balamuthiasis is difficult to diagnose because of the rarity of this disease, the nonspecific symptoms and signs, and lack of awareness among clinicians. In cases of suspected B. mandrillaris infection, the CDC in the USA can be contacted for immediate consultation. Free-living amoebae are rarely isolated from the CSF, and thus, an antemortem diagnosis without brain biopsy is challenging. The CSF analysis when performed often reveals nonspecific lymphocytic pleocytosis with normal/low glucose and elevated protein levels. Microscopic examination of tissue sections from biopsy specimens stained with hematoxylin and eosin (H&E) or periodic acid-Schiff (PAS) may demonstrate amebic trophozoites and/or cysts with morphology typical of Balamuthia scattered in the perivascular space [19]. Other hallmarks on biopsy include characteristic granuloma formation with CD4 and CD8 T cells, B lymphocytes with few plasma cells, macrophages, and multinucleated giant cells. The major disadvantage of microscopy is the need for significant expertise regarding the morphological characteristics of B. mandrillaris and the availability of a high-quality tissue sample. Immunohistochemistry has been widely used in the detection of the morphological forms of the parasite, and this technique also reliably differentiates B. mandrillaris from Acanthamoeba spp [20]. PCR-based methods analyze the organism’s ribosomal RNA gene sequences (16s rRNA or 18s rRNA), and they are more sensitive and specific in diagnosing B. mandrillaris, requiring little pathogen-specific expertise [3]. The major advantage of PCR-based techniques is that the genetic material can be detected either in the CSF or blood, and it eliminates the need for invasive tissue biopsy. A real-time PCR is superior to conventional PCR as it is quicker and reduces the risk of contamination. To avoid false-positive results due to cross reactivity and false-negative results due to novel variants or mutants in the target gene, the identification by PCR should involve the detection of at least 2 independent areas of the pathogen’s genome in parallel. A novel target (RNase P gene) of the B. mandrillaris primer set can be combined with the 18S rRNA gene in a duplex real-time PCR assay to ensure maximum specificity [21]. A triplex real-time TaqMan PCR assay has been developed by the CDC, which can simultaneously detect Acanthamoeba spp., B. mandrillaris, and N. fowleri. The triplex assay has high specificity and a rapid test completion time of less than 5 hours [22]. Nested PCR can be used to detect the organism directly in soil and water samples [23]. Alternatively, metagenomic deep sequencing is a rapid diagnostic tool for patients with difficult-to-diagnose Balamuthia encephalitis [24].

Balamuthia GAE has a high case fatality rate of more than 95%, with only 10 reported cases of patients surviving this deadly CNS infection. Various combinations of antimicrobials have been used with disappointing results. The failure of antimicrobial therapy is primarily due to their poor CSF penetration and the thick cell wall of the amebic cyst. Pentamidine, flucytosine, fluconazole, sulfadiazine, and either azithromycin or clarithromycin have been used in patients who have survived the infection [25]; all of these drugs were given to our patient. Miltefosine, previously used for leishmaniasis, has shown some promise and is approved by the U.S. Food and Drug Administration as an investigational treatment for BAE [26]; that too was given to our patient. The optimal duration of combination drug therapy for GAE is unknown, but most survivors had been treated for a few months up to more than 5 years. Survivors of GAE cases often suffer from permanent neurocognitive disorders due to the extensive cerebral edema that develops during the course of the illness. In the absence of effective treatment, prevention is the most effective strategy for BAE. As this infection is more common in agricultural workers or persons with regular contact with soil, certain simple precautionary measures should be taken to prevent B. mandrillaris from entering the host. For example, individuals with skin lesions should wear protective clothing while working in soil.

Three other species of free-living amoeba, Acanthamoeba spp., Sappinia pedata, and Naegleria fowleri, have also been implicated in central nervous system infections. Acanthamoeba spp. and Sappinia pedata can cause granulomatous amebic encephalitis (GAE), similar to BAE, particularly in immunocompromised hosts [27, 28]. In acanthamoebiasis, the clinical outcome is impacted by surgical debulking, early initiation of antimicrobial therapy, and the immune status of the host. Voriconazole and miltefosine are two promising oral agents with in vitro activity against Acanthamoeba, and they have excellent brain parenchymal and CSF penetration. Naegleria fowleri, commonly referred to as “brain-eating amoeba”, causes an acute and fulminant, necrotizing infection of the brain called primary amebic meningoencephalitis (PAM) in children and adults with a history of recent exposure to warm fresh water [29]. There is a high mortality rate probably exceeding 98% patients in patients with PAM. Early triple therapy with intravenous amphotericin B and fluconazole and oral administration of rifampicin can offer some hope of cure for this devastating disease [30].

4. Conclusions

Balamuthia mandrillaris is a free-living amoeba found in soil that can cause fatal granulomatous amebic encephalitis in both healthy and immunocompromised patients. Although Balamuthia amebic encephalitis is rare, clinicians should maintain a high index of clinical suspicion of Balamuthia in a patient with subacute granulomatous meningoencephalitis and a negative workup for viral, bacterial, and fungal infections, particularly if they had been exposed to soil during work or recreational activities. Brain biopsy is crucial for arriving at the correct diagnosis. Even though multiple combination antimicrobials have been tried, the prognosis of granulomatous amebic encephalitis is dismal. Future studies are essential to identify novel drugs that can penetrate the BBB and treat BAE more effectively.

Conflicts of Interest

The authors declare that they have no conflicts of interest.


The authors would like to thank the Division of Infectious Diseases of the Department of Internal Medicine at the Texas Health Presbyterian Hospital Dallas for their help and support.


  1. K. Takei, M. Toyoshima, M. Nakamura et al., “An acute case of granulomatous amoebic encephalitis-Balamuthia mandrillaris infection,” Internal Medicine, vol. 57, no. 9, pp. 1313–1316, 2018. View at: Publisher Site | Google Scholar
  2. G. S. Visvesvara, A. J. Martinez, F. L. Schuster et al., “Leptomyxid amoeba, a new agent of amebic meningoencephalitis in humans and animals,” Journal of Clinical Microbiology, vol. 28, no. 12, pp. 2750–2756, 1990. View at: Google Scholar
  3. G. C. Booton, J. R. Carmichael, G. S. Visvesvara, T. J. Byers, and P. A. Fuerst, “Genotyping of Balamuthia mandrillaris based on nuclear 18S and mitochondrial 16S rRNA genes,” American Journal of Tropical Medicine and Hygiene, vol. 68, no. 1, pp. 65–69, 2003. View at: Publisher Site | Google Scholar
  4. P. Goñi, M. T. Fernández, and E. Rubio, “Identifying endosymbiont bacteria associated with free-living amoebae,” Environmental Microbiology, vol. 16, no. 2, pp. 339–349, 2014. View at: Publisher Site | Google Scholar
  5. J. H. Diaz, “The public health threat from Balamuthia mandrillaris in the southern United States,” Journal of the Louisiana State Medical Society, vol. 163, no. 4, pp. 197–204, 2011. View at: Google Scholar
  6. R. Siddiqui and N. A. Khan, “Balamuthia amoebic encephalitis: an emerging disease with fatal consequences,” Microbial Pathogenesis, vol. 44, no. 2, pp. 89–97, 2008. View at: Publisher Site | Google Scholar
  7. A. Matin, R. Siddiqui, S. Jayasekera, and N. A. Khan, “Increasing importance of Balamuthia mandrillaris,” Clinical Microbiology Reviews, vol. 21, no. 3, pp. 435–448, 2008. View at: Publisher Site | Google Scholar
  8. A. J. Martinez, A. E. Guerra, J. Garcia-Tamayo, G. Cespedes, and J. E. Gsonzalez-Alfonzo, “Granulomatous amebic encephalitis: a review and report of a spontaneous case from Venezuela,” Acta Neuropathologica, vol. 87, no. 4, pp. 430–434, 1994. View at: Publisher Site | Google Scholar
  9. T. H. Dunnebacke, F. L. Schuster, S. Yagi, and G. C. Booton, “Balamuthia mandrillaris from soil samples,” Microbiology, vol. 150, no. 9, pp. 2837–2842, 2004. View at: Publisher Site | Google Scholar
  10. F. L. Schuster, T. H. Dunnebacke, G. C. Booton et al., “Environmental isolation of Balamuthia mandrillaris associated with a case of amebic encephalitis,” Journal of Clinical Microbiology, vol. 41, no. 7, pp. 3175–3180, 2003. View at: Publisher Site | Google Scholar
  11. S. Parija, H. Venugopal, and K. P. Dinoop, “Management of granulomatous amebic encephalitis: laboratory diagnosis and treatment,” Tropical Parasitology, vol. 5, no. 1, pp. 23–28, 2015. View at: Publisher Site | Google Scholar
  12. S. Jayasekera, J. Sissons, C. Tucker et al., “Post-mortem culture of Balamuthia mandrillaris from the brain and cerebrospinal fluid of a case of granulomatous amoebic meningoencephalitis, using human brain microvascular endothelial cells,” Journal of Medical Microbiology, vol. 53, no. 10, pp. 1007–1012, 2004. View at: Publisher Site | Google Scholar
  13. S. Jayasekera, A. Matin, J. Sissons, A. H. Maghsood, and N. A. Khan, “Balamuthia mandrillaris stimulates interleukin-6 release in primary human brain microvascular endothelial cells via a phosphatidylinositol 3-kinase-dependent pathway,” Microbes and Infection, vol. 7, no. 13, pp. 1345–1351, 2005. View at: Publisher Site | Google Scholar
  14. E. C. Farnon, K. E. Kokko, P. J. Mbaeyi et al., “Transmission of Balamuthia mandrillaris by organ transplantation,” Clinical Infectious Diseases, vol. 63, no. 7, pp. 878–888, 2016. View at: Publisher Site | Google Scholar
  15. Centers for Disease Control and Prevention, “Notes from the field: transplant-transmitted Balamuthia mandrillaris-Arizona, 2010,” American Journal of Transplantation, vol. 59, p. 1182, 2010. View at: Google Scholar
  16. J. F. Healy, “Balamuthia amebic encephalitis: radiographic and pathologic findings,” American Journal of Neuroradiology (AJNR), vol. 23, no. 3, pp. 486–489, 2002. View at: Google Scholar
  17. B. J. Duke, W. Tyson, R. DeBiasi, J. E. Freeman, and K. R. Winston, “Balamuthia mandrillaris meningoencephalitis presenting with acute hydrocephalus,” Pediatric Neurosurgery, vol. 26, no. 2, pp. 107–111, 2008. View at: Publisher Site | Google Scholar
  18. T. Y. Y. Ong, N. A. Khan, and R. Siddiqui, “Brain-eating amoebae: predilection sites in the brain and disease outcome,” Journal of Clinical Microbiology, vol. 55, no. 7, pp. 1989–1997, 2017. View at: Publisher Site | Google Scholar
  19. A. J. Martínez, F. L. Schuster, and G. S. Visvesvara, “Balamuthia mandrillaris: its pathogenic potential,” Journal of Eukaryotic Microbiology, vol. 48, pp. 6S–9S, 2001. View at: Publisher Site | Google Scholar
  20. B. da Rocha-Azevedo, H. B. Tanowitz, and F. Marciano-Cabral, “Diagnosis of infections caused by pathogenic free-living amoebae,” Interdisciplinary Perspectives on Infectious Diseases, vol. 2009, Article ID 251406, 14 pages, 2009. View at: Publisher Site | Google Scholar
  21. A. F. Kiderlen, E. Radam, and A. Lewin, “Detection of Balamuthia mandrillaris DNA by real-time PCR targeting the RNase P gene,” BMC Microbiology, vol. 8, no. 1, p. 210, 2008. View at: Publisher Site | Google Scholar
  22. Y. Qvarnstrom, G. S. Visvesvara, R. Sriram, and A. J. da Silva, “Multiplex real-time PCR assay for simultaneous detection of Acanthamoeba spp., Balamuthia mandrillaris, and Naegleria fowleri,” Journal of Clinical Microbiology, vol. 44, no. 10, pp. 3589–3595, 2006. View at: Publisher Site | Google Scholar
  23. A. F. Ahmad, P. W. Andrew, and S. Kilvington, “Development of a nested PCR for environmental detection of the pathogenic free-living amoeba Balamuthia mandrillaris,” Journal of Eukaryotic Microbiology, vol. 58, no. 3, pp. 269–271, 2011. View at: Publisher Site | Google Scholar
  24. M. R. Wilson, N. M. Shanbhag, M. J. Reid et al., “Diagnosing Balamuthia mandrillaris encephalitis with metagenomic deep sequencing,” Annals of Neurology, vol. 78, no. 5, pp. 722–730, 2015. View at: Publisher Site | Google Scholar
  25. M. E. Vollmer and C. Glaser, “A Balamuthia survivor,” JMM Case Reports, vol. 3, no. 3, Article ID e005031, 2016. View at: Publisher Site | Google Scholar
  26. P. P. Dilanchian, J. C. Chan, A. C. Sanchez et al., “Balamuthia mandrillaris and Acanthamoeba amebic encephalitis with neurotoxoplasmosis coinfection in a patient with advanced HIV Infection,” Journal of Clinical Microbiology, vol. 50, no. 3, pp. 1128–1131, 2012. View at: Publisher Site | Google Scholar
  27. J. E. Bennett, R. Dolin, and M. J. Blaser, Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, Elsevier/Saunders, Philadelphia, PA, USA, 8th edition, 2015.
  28. Y. Qvarnstrom, A. J. da Silva, F. L. Schuster et al., “Molecular confirmation of Sappinia pedata as a causative agent of amoebic encephalitis,” Journal of Infectious Diseases, vol. 199, no. 8, pp. 1139–1142, 2009. View at: Publisher Site | Google Scholar
  29. L. G. Capewell, A. M. Harris, J. S. Yoder et al., “Diagnosis, clinical course, and treatment of primary amoebic meningoencephalitis in the United States, 1937–2013,” Journal of the Pediatric Infectious Diseases Society, vol. 4, no. 4, pp. e68–e75, 2014. View at: Publisher Site | Google Scholar
  30. W. M. Linam, M. Ahmed, J. R. Cope et al., “Successful treatment of an adolescent with Naegleria fowleri primary amebic meningoencephalitis,” Pediatrics, vol. 135, no. 3, pp. e744–e748, 2015. View at: Publisher Site | Google Scholar

Copyright © 2019 Binoy Yohannan and Mark Feldman. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

2284 Views | 445 Downloads | 1 Citation
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.